Cytidine deaminases and methods of genome editing using the same
US-2024327859-A1 · Oct 3, 2024 · US
US8999317B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8999317-B2 |
| Application number | US-51313407-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 1, 2007 |
| Priority date | Nov 1, 2006 |
| Publication date | Apr 7, 2015 |
| Grant date | Apr 7, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are methods and compositions related to the structure and function of APOBEC3G.
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting viral infectivity in a cell comprising administering an inhibitor of the interaction between low molecular mass APOBEC3 G (LMM) dimers and high molecular mass APOBEC3G (HMM) conversion molecules to the cell, wherein the inhibitor stabilizes the LMM dimer, thereby inhibiting viral infectivity in the cell, wherein the inhibitor is selected from the group consisting of a small molecule, a peptide, a nucleic acid molecule, an antibody, and…
Physics · mapped topic
Physics · mapped topic
Human Necessities · mapped topic
Physics · mapped topic
Chemistry & Metallurgy · mapped topic
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.